Contraception and Family Planning Practice Questions

Q: What is the most preferable contraceptive device for a female with Rheumatic Heart Disease who has completed her family?

Tubal ligation. **Explanation:** The primary concern in managing contraception for a patient with **Rheumatic Heart Disease (RHD)** is preventing unintended pregnancy, which poses a high risk of cardiac decompensation due to the physiological hemodynamic changes of pregnancy. **Why Tubal Ligation is Correct:** For a woman who has **completed her family**, permanent sterilization via **Tubal Ligation** is the most preferable method. It offers the highest efficacy (lowest failure rate) without the hormonal risks or infection concerns associated with other methods. In RHD patients, it is ideally performed during a stable cardiac period. It provides a "one-time" solution to the high-risk threat of future pregnancies. **Analysis of Incorrect Options:** * **IUCD (Option A):** Generally avoided in RHD patients due to the risk of **Pelvic Inflammatory Disease (PID)** and subsequent **Subacute Bacterial Endocarditis (SABE)**. Additionally, the vasovagal response during insertion can trigger cardiac arrhythmias in susceptible patients. * **Norplant (Option C):** While highly effective, progestin-only implants are usually reserved for those spacing pregnancies. For someone who has completed their family, permanent methods are superior. * **Barrier Method (Option D):** These have a high **user-failure rate**. In RHD, a contraceptive failure leading to pregnancy can be life-threatening; therefore, low-efficacy methods are not preferred. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Eligibility Criteria:** For RHD, sterilization is Category 2 (benefits outweigh risks), but IUCD is often Category 3/4 if there is a high risk of endocarditis. * **Prophylaxis:** If an IUCD must be used or surgery performed, **antibiotic prophylaxis** is mandatory to prevent SABE. * **OCPs:** Combined Oral Contraceptive Pills are **contraindicated** in RHD with complications (like atrial fibrillation or valve replacement) due to the increased risk of thromboembolism.

Q: What is the failure rate per year of the Pearl Index?

1200. **Explanation:** The **Pearl Index** is the most common method used in clinical trials to report the effectiveness of a contraceptive method. It calculates the number of unintended pregnancies per 100 woman-years of exposure. The formula for the Pearl Index is: $$\text{Pearl Index} = \frac{\text{Total number of pregnancies} \times 1200}{\text{Total number of months of exposure}}$$ **Why 1200 is the correct answer:** The number **1200** represents the total number of months in 100 years (12 months × 100 women). By multiplying the pregnancies by 1200 and dividing by the total months of use, the result expresses the failure rate per **100 woman-years**. For example, a Pearl Index of 1 means that if 100 women use a specific method for one year, one woman is likely to become pregnant. **Analysis of Options:** * **Option A & C (1200):** Correct. This is the standard constant used to normalize the data to 100 woman-years. * **Option B & D (2400):** Incorrect. This value has no mathematical basis in the standard Pearl Index calculation. **High-Yield Clinical Pearls for NEET-PG:** * **Lowest Pearl Index (Most Effective):** Implant (0.05), followed by Vasectomy and IUCD (LNG-IUS). * **Highest Pearl Index (Least Effective):** Barrier methods (Condoms) and natural methods (Rhythm method). * **Alternative Metric:** The **Life Table Analysis** is considered more accurate than the Pearl Index because it calculates failure rates at specific intervals (e.g., month-by-month), accounting for users who drop out of a study over time. * **Perfect Use vs. Typical Use:** Always distinguish between these; typical use failure rates are always higher due to human error.

Q: What is the role of progestogens?

All of the above. Progestogens (synthetic progesterone) are fundamental components of hormonal contraception and hormone replacement therapy. Their multifaceted roles make **Option D** the correct answer. **1. Inhibition of Ovulation (Option A):** Progestogens exert a negative feedback effect on the hypothalamus and the anterior pituitary. This suppresses the secretion of **GnRH** and **LH (Luteinizing Hormone)**. By preventing the mid-cycle LH surge, progestogens effectively inhibit ovulation. This is the primary mechanism of action in Progesterone-Only Pills (POPs) and injectable contraceptives (DMPA). **2. Protection against Endometrial Cancer (Option B):** Unopposed estrogen causes endometrial proliferation, which increases the risk of hyperplasia and malignancy. Progestogens counteract this by inducing a "secretory" phase, limiting endometrial growth, and promoting cellular differentiation. In clinical practice, progestogens are added to Estrogen Replacement Therapy (ERT) specifically to neutralize the risk of endometrial cancer. **3. Prompt Withdrawal Bleeding (Option C):** In a "Progesterone Challenge Test," the administration and subsequent withdrawal of progestogen lead to the shedding of an estrogen-primed endometrium. This confirms the presence of adequate endogenous estrogen and a patent outflow tract, making it a diagnostic tool for secondary amenorrhea. **High-Yield NEET-PG Pearls:** * **Contraceptive Mechanism:** Besides inhibiting ovulation, progestogens thicken cervical mucus (hostile to sperm) and cause endometrial atrophy (preventing implantation). * **DMPA (Antara):** A 150mg IM injection given every 3 months; its main side effect is irregular bleeding or amenorrhea. * **Centchroman (Saheli):** A non-steroidal SERM (Selective Estrogen Receptor Modulator) used in the National Family Welfare Programme; it is **not** a progestogen.

Q: Which of the following is NOT an absolute contraindication for IUCD users?

HIV infection. The correct answer is **C. HIV infection**. ### **Explanation** According to the **WHO Medical Eligibility Criteria (MEC)** for contraceptive use, HIV infection is categorized as **MEC Category 2** (benefits generally outweigh risks) for both initiation and continuation of an Intrauterine Contraceptive Device (IUCD). It is **not** an absolute contraindication. Women with HIV, including those on Antiretroviral Therapy (ART) who are clinically well, can safely use IUCDs. The risk of pelvic infection is not significantly higher in these patients compared to HIV-negative women, provided they do not have an active AIDS-defining illness (MEC 3 for initiation). ### **Why other options are wrong:** * **Undiagnosed vaginal bleeding (MEC 4):** This is an absolute contraindication because the bleeding could be due to an underlying malignancy (e.g., cervical or endometrial cancer) or pregnancy complications, which must be ruled out before insertion. * **Suspected pregnancy (MEC 4):** Insertion of an IUCD during pregnancy can lead to septic abortion, miscarriage, or preterm labor. Pregnancy must always be excluded. * **Pelvic Inflammatory Disease (PID) (MEC 4):** Current or active PID is an absolute contraindication for initiation. Inserting an IUCD during an active infection can exacerbate the condition and lead to tubal damage or infertility. ### **High-Yield Clinical Pearls for NEET-PG:** * **MEC Category 4 (Absolute Contraindications):** Undiagnosed vaginal bleeding, current PID, suspected pregnancy, copper allergy (for Cu-T), and distorted uterine cavity (fibroids). * **IUCD & HIV:** If a woman develops AIDS while using an IUCD, she can continue using it (MEC 2), but initiation in a patient with AIDS who is not on ART is MEC 3. * **Ideal Candidate:** A parous woman in a stable monogamous relationship with no history of PID. * **Most common side effect:** Bleeding (menorrhagia); **Most common reason for removal:** Pain and bleeding.

Q: What is the mechanism of action of the progesterone component in oral contraceptive pills?

All of the above. The progesterone component of Combined Oral Contraceptive Pills (COCPs) and Progesterone-Only Pills (POPs) acts through multiple synergistic mechanisms to ensure high contraceptive efficacy. ### **Mechanism of Action** 1. **Prevention of Ovulation (Primary Mechanism):** Progesterone exerts negative feedback on the hypothalamus and anterior pituitary. This suppresses the release of **GnRH** and **LH (Luteinizing Hormone)**. By preventing the LH surge, ovulation is inhibited. 2. **Alteration of Cervical Mucus:** Progesterone makes the cervical mucus **thick, viscid, and scanty**. This creates a "hostile" environment that prevents sperm penetration into the upper reproductive tract. 3. **Inhibition of Implantation:** It induces "hostile endometrium" by causing premature secretory changes followed by endometrial atrophy. This makes the lining unreceptive to a fertilized ovum. 4. **Tubal Motility:** It also decreases the motility and ciliary activity of the fallopian tubes, slowing the transport of the ovum/zygote. ### **Why "All of the Above" is Correct** While ovulation inhibition is the most potent effect in COCPs, the alterations in cervical mucus and endometrium serve as critical "backup" mechanisms. In POPs (Minipill), the cervical mucus effect is often the primary mechanism as they do not consistently suppress ovulation. ### **High-Yield NEET-PG Pearls** * **Estrogen's Role:** In COCPs, estrogen primarily suppresses **FSH** (preventing follicular development) and stabilizes the endometrium to provide cycle control (preventing breakthrough bleeding). * **Most Sensitive Indicator:** The thickening of cervical mucus is the earliest effect of progesterone. * **Pearl:** For a patient on POPs, if a pill is delayed by more than **3 hours**, backup contraception is needed because the cervical mucus effect wears off rapidly.

Q: Fimbriectomy is also known as:

Kroener's procedure. **Explanation:** **Kroener’s procedure** is the correct answer because it specifically refers to a **fimbriectomy**. In this technique, the distal portion of the fallopian tube, including the entire fimbria, is ligated and excised. While it is a simple procedure, it is rarely performed today because it is associated with a higher failure rate (due to recanalization or incomplete removal) and is virtually irreversible compared to mid-segment techniques. **Analysis of Incorrect Options:** * **A. Pomeroy technique:** This is the most commonly used method of tubal ligation. It involves picking up a loop of the mid-portion of the tube, ligating the base with absorbable suture (plain catgut), and excising the loop. * **B. Uchida’s procedure:** A complex technique involving sub-mesosalpingeal injection of saline/adrenaline, stripping the serosa, and burying the proximal stump into the broad ligament while leaving the distal stump in the peritoneal cavity. It has the lowest failure rate. * **C. Irving’s procedure:** This involves severing the tube and burying the proximal stump into a tunnel created in the posterior wall of the uterus. It is highly effective but usually performed during a Cesarean section due to the required exposure. **High-Yield Clinical Pearls for NEET-PG:** * **Most common method:** Pomeroy’s technique (due to simplicity and safety). * **Most effective method (lowest failure rate):** Uchida’s technique. * **Best time for postpartum sterilization:** 24–48 hours after delivery. * **Failure rates:** Usually expressed via the **Pearl Index**. For tubal sterilization, the failure rate is approximately 0.5 per 100 woman-years. * **Legal aspect:** In India, the **MTP Act** does not govern sterilization; it is a voluntary procedure requiring informed consent (usually under the Supreme Court guidelines).

Q: Which of the following is a true statement about the minipill?

Irregular vaginal bleeding may be a side effect.. The **Minipill**, or Progestogen-Only Pill (POP), is a contraceptive containing only a low dose of progestin without estrogen. ### **Explanation of Options** * **A. Irregular vaginal bleeding (Correct):** This is the most common side effect of POPs. Unlike combined pills, which provide a predictable withdrawal bleed due to the estrogen component stabilizing the endometrium, POPs often cause endometrial thinning and breakthrough spotting. Approximately 40% of users experience irregular bleeding, spotting, or amenorrhea. * **B. Combination with OCPs:** This is incorrect. The minipill is an alternative to Combined Oral Contraceptive Pills (COCPs), especially for women who have contraindications to estrogen (e.g., history of thromboembolism or hypertension). * **C. Use during lactation:** This is incorrect. The minipill is the **contraceptive of choice for lactating mothers**. Unlike estrogen, which suppresses milk production, progestins do not affect the quantity or quality of breast milk. * **D. Ectopic pregnancy:** This is incorrect. While the minipill reduces the absolute risk of pregnancy, if a woman *does* conceive while taking it, there is a **higher relative risk** that the pregnancy will be ectopic because progestins decrease fallopian tube motility. ### **High-Yield NEET-PG Pearls** * **Mechanism of Action:** Primarily works by **thickening cervical mucus** (preventing sperm penetration) and making the endometrium unfavorable for implantation. It does not consistently inhibit ovulation (ovulation occurs in ~60% of cycles). * **Strict Timing:** The minipill must be taken at the **same time every day**. A delay of more than **3 hours** is considered a "missed pill," requiring backup contraception for 48 hours. * **Ideal Candidate:** Lactating women, smokers over 35, and women with cardiovascular risks.

Q: A pregnant woman with an intrauterine contraceptive device (IUCD) in situ, where the IUCD tail is visible, what is the next recommended course of action?

Remove the IUCD. ### Explanation The management of a pregnancy with an intrauterine contraceptive device (IUCD) in situ depends primarily on the **visibility of the strings**. **Why Option B is Correct:** When a woman becomes pregnant with an IUCD and the strings are visible, the standard of care is **immediate removal of the IUCD**. Leaving the device in situ significantly increases the risk of: 1. **Septic Abortion:** A 20-fold increase in risk. 2. **Spontaneous Abortion (SAB):** The risk of SAB is approximately 50% if left in situ, which reduces to about 20–25% if the device is removed early. 3. **Preterm Labor and Chorioamnionitis:** Increased risk in the second and third trimesters. **Why Other Options are Incorrect:** * **Options A & C:** Continuing the pregnancy without intervention or just monitoring is dangerous due to the high risk of life-threatening pelvic sepsis and miscarriage. * **Option D:** Pregnancy termination is not medically mandated. If the woman desires to continue the pregnancy, the IUCD should be removed, and the pregnancy can proceed. The IUCD itself is **not teratogenic**. **High-Yield Clinical Pearls for NEET-PG:** * **Strings NOT visible:** Perform an ultrasound. If the IUCD is intra-decidual, **do not** attempt removal, as it may disrupt the gestational sac. * **Ectopic Risk:** While IUCDs are highly effective, if a pregnancy *does* occur, the **relative risk** of it being an ectopic pregnancy is higher (though the absolute risk is lower than in non-contraceptive users). * **Teratogenicity:** There is no evidence of increased congenital malformations in babies born with an IUCD in situ. * **Management Summary:** Strings visible $\rightarrow$ Pull/Remove; Strings not visible $\rightarrow$ Leave it alone and monitor.

Question 1

What is the most preferable contraceptive device for a female with Rheumatic Heart Disease who has completed her family?

Accepted Answer

Tubal ligation

Answer

Intrauterine contraceptive device (IUCD)

Answer

Norplant

Answer

Barrier method

Question 2

What is the failure rate per year of the Pearl Index?

Accepted Answer

1200

Answer

2400

Answer

2400

Question 3

All of the following are features of post-tubal ligation syndrome except?

Accepted Answer

All the above

Answer

Abnormal menstrual bleeding

Answer

Dysmenorrhea

Answer

Dyspareunia

Question 4

What is the role of progestogens?

Accepted Answer

All of the above

Answer

Inhibits ovulation

Answer

Protects against endometrial cancer

Answer

Causes prompt withdrawal bleeding

Question 5

Which of the following is NOT an absolute contraindication for IUCD users?

Accepted Answer

HIV infection

Answer

Undiagnosed vaginal bleeding

Answer

Suspected pregnancy

Answer

Pelvic inflammatory disease

Question 6

What is the mechanism of action of the progesterone component in oral contraceptive pills?

Accepted Answer

All of the above

Answer

Preventing ovulation

Answer

Inhibiting implantation

Answer

Causing alterations in cervical mucus

Question 7

Fimbriectomy is also known as:

Accepted Answer

Kroener's procedure

Answer

Pomeroy technique

Answer

Uchid's procedure

Answer

Irving's procedure

Question 8

The Pomeroy technique is used for which of the following procedures?

Accepted Answer

Tubal ligation

Answer

Laparoscopy

Answer

Hysteroscopy

Answer

Mini laparotomy

Question 9

Which of the following is a true statement about the minipill?

Accepted Answer

Irregular vaginal bleeding may be a side effect.

Answer

It is used in combination with oral contraceptive pills.

Answer

It cannot be used during lactation.

Answer

It prevents ectopic pregnancy.

Question 10

A pregnant woman with an intrauterine contraceptive device (IUCD) in situ, where the IUCD tail is visible, what is the next recommended course of action?

Accepted Answer

Remove the IUCD

Answer

Continue the pregnancy without intervention

Answer

Continue the pregnancy with watchful monitoring

Answer

Remove the IUCD and terminate the pregnancy

Contraception and Family Planning — MCQs

Contraception and Family Planning — MCQs

On this page

Practice by Chapter

Want unlimited practice?